Daewoong Pharmaceutical Co., Ltd (KRX:069620)
128,800
+3,900 (3.12%)
Aug 28, 2026, 3:30 PM KST
Daewoong Pharmaceutical Revenue
Daewoong Pharmaceutical had revenue of 448.46B KRW in the quarter ending June 30, 2026, with 10.61% growth. This brings the company's revenue in the last twelve months to 1.64T, up 9.87% year-over-year. In the year 2025, Daewoong Pharmaceutical had annual revenue of 1.57T with 10.42% growth.
Revenue (ttm)
1.64T
Revenue Growth
+9.87%
P/S Ratio
0.91
Revenue / Employee
994.66M
Employees
1,644
Market Cap
1.48T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.57T | 148.21B | 10.42% |
| Dec 31, 2024 | 1.42T | 47.35B | 3.44% |
| Dec 31, 2023 | 1.38T | 95.24B | 7.44% |
| Dec 31, 2022 | 1.28T | 127.12B | 11.03% |
| Dec 31, 2021 | 1.15T | 97.55B | 9.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Daewoong | 2.12T |
| GC Biopharma | 2.04T |
| Chong Kun Dang Pharmaceutical | 1.74T |
| Dong-A Socio Holdings | 1.52T |
| Boryung | 1.03T |
| JW Pharmaceutical | 820.86B |
| Ildong Pharmaceutical | 582.33B |
| Celltrion Pharm | 274.73B |
Daewoong Pharmaceutical News
- 2 months ago - Arcera Life Sciences and Daewoong Expand Strategic Partnership to Bring Enavogliflozin to the Middle East - Financial Post
- 1 year ago - Sun Pharma launches FEXUCLUE 40 mg in India for treatment of Erosive Esophagitis - Business Upturn